Jiangsu (SH:688426) Zhong Guo Jing Ji Wang·2025-10-16 07:14Core Viewpoint - 康为世纪 reported a significant increase in revenue for the first half of 2025, but continued to face net losses, indicating ongoing financial challenges despite growth in sales [1][2]. Financial Performance - The company achieved operating revenue of 87.12 million yuan in the first half of 2025, representing a year-on-year increase of 29.74% [1][2]. - The net profit attributable to shareholders was -55.91 million yuan, compared to -50.06 million yuan in the same period last year, reflecting an increase in losses of 11.70% [1][2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -66.56 million yuan, compared to -61.15 million yuan in the previous year, marking an 8.84% increase in losses [1][2]. - The net cash flow from operating activities was -49.66 million yuan, an improvement of 16.15% from -59.22 million yuan in the same period last year [1][2]. Historical Context - 康为世纪 was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 25, 2022, with an issuance price of 48.98 yuan per share, raising a total of 1.14 billion yuan [3]. - The company’s net fundraising amount was 1.05 billion yuan after deducting issuance costs, exceeding the original plan by 68.63 million yuan [3]. - The funds raised are intended for projects related to medical devices, biological testing reagents, marketing network construction, and molecular detection product development [3]. Shareholder Actions - On June 6, 2023, 康为世纪 announced a dividend plan, distributing 5.2 yuan (pre-tax) for every 10 shares and a bonus issue of 2 shares [4].